Pfizer responds to announcement that inotuzumab ozogamicin has been accepted for use by the Scottish Medicines Consortium (SMC) for the treatment of adults with relapsed or refractory (R/R) CD22-positive B-cell precursor acute lymphoblastic leukaemia (ALL) in patients for whom the intent is to proceed to stem cell transplantation.
Mark Drummond, Consultant Haematologist, Beatson West of Scotland Cancer Centre, said: “Today’s decision from the SMC is good news for patients with relapsed or refractory ALL. Until now, patients have had very few treatment options available to them and often face a poor prognosis and a typical survival of only 3-5 months. The approval of inotuzumab ozogamicin in Scotland means that eligible patients now have access to a new treatment option which may provide the opportunity for them to progress to a stem cell transplant, the only potential cure for this aggressive blood cancer.”
Craig Eagle, Head of Oncology, Pfizer UK said: “We are delighted that patients in Scotland will now have routine access to inotuzumab ozogamicin, an important medicine which has been shown to help some of the most vulnerable leukaemia patients achieve complete remission. Following this good news in Scotland, we remain focused on continuing discussions with NICE with the aim to ensure this medicine can be made available to all eligible patients across the UK.”